Cited by 26Thyroid Disorders and TreatmentsEstrogen and related hormone effectsGrowth Hormone and Insulin-like Growth Factors

Thyroid hormone resistance: mechanisms and therapeutic development

Yao, Benqiang, Yang, Chunyan, Pan, Chengxi, Li, Yong·2022·Molecular and Cellular Endocrinology

Abstract

As an essential primary hormone, thyroid hormone (TH) is indispensable for human growth, development and metabolism. Impairment of TH function in several aspects, including TH synthesis, activation, transportation and receptor-dependent transactivation, can eventually lead to thyroid hormone resistance syndrome (RTH). RTH is a rare syndrome that manifests as a reduced target cell response to TH signaling. The majority of RTH cases are related to thyroid hormone receptor β (TRβ) mutations, and only a few RTH cases are associated with thyroid hormone receptor α (TRα) mutations or other causes. Patients with RTH suffer from goiter, mental retardation, short stature and bradycardia or tachycardia. To date, approximately 170 mutated TRβ variants and more than 20 mutated TRα variants at the amino acid level have been reported in RTH patients. In addition to these mutated proteins, some TR isoforms can also reduce TH function by competing with primary TRs for TRE and RXR binding. Fortunately, different treatments for RTH have been explored with structure-activity relationship (SAR) studies and drug design, and among these treatments. With thyromimetic potency but biochemical properties that differ from those of primary TH (T3 and T4), these TH analogs can bypass specific defective transporters or reactive mutant TRs. However, these compounds must be carefully applied to avoid over activating TRα, which is associated with more severe heart impairment. The structural mechanisms of mutation-induced RTH in the TR ligand-binding domain are summarized in this review. Furthermore, strategies to overcome this resistance for therapeutic development are also discussed.

Integrity signals

Registry

Crossref · 10.1016/j.mce.2022.111679

Cites

252 of 252 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Thyroid hormone analogues have been studied for symptom improvement in THR while avoiding overstimulation of the alpha thyroid hormone receptor, which could worsen cardiac prognosis.

    “In the case of THR, there is no therapy that completely corrects the underlying defect, but treatments with thyroid hormone analogs have been investigated to improve symptoms without excessive activation of the a thyroid hormone receptor, which would worsen cardiac prognosis.91”
  • No therapy completely corrects the underlying defect in thyroid hormone resistance.

    “In the case of THR, there is no therapy that completely corrects the underlying defect, but treatments with thyroid hormone analogs have been investigated to improve symptoms without excessive activation of the a thyroid hormone receptor, which would worsen cardiac prognosis.91”

Cites

Flagged first, then by citations

5 of the 257 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Yao, B., Yang, C., Pan, C., & Li, Y.
Affiliations
Xiamen University (CN)
Corresponding author
  • Yang, Chunyan
  • Li, Yong
Venue
Molecular and Cellular Endocrinology
Publisher
Elsevier BV
Published
2022-08
Volume
553
Pages
111679
ISSN
0303-7207 (ISSN-L)
OpenAlex
W4283168004
Cited by
26
References
257
Citations by year
2026: 5 · 2025: 6 · 2024: 6 · 2023: 9
FWCI
3.89
Type
journal article
Language
en
Open access
closed
Locations
  • Molecular and Cellular Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
Keywords
thyroid hormone resistance, thyroid hormone receptor beta, thyroid hormone receptor alpha, structure-activity relationship, drug design, goiter, bradycardia, short stature, intellectual disability
MeSH terms
Humans, Mutation, Receptors, Thyroid Hormone, Thyroid Hormones, Triiodothyronine, Thyroid Hormone Resistance Syndrome, Thyroid Hormone Receptors alpha, Thyroid Hormone Receptors beta

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review